Globus Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3795772082
USD
88.74
0.99 (1.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Globus Medical, Inc. stock-summary
stock-summary
Globus Medical, Inc.
Pharmaceuticals & Biotechnology
Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company's products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. QUARTEX is its Occipito-Cervico-Thoracic (OCT) stabilization system. QUARTEX features a threading locking cap to enable low-torque. The Company's portfolio of approved and pipeline Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques.
Company Coordinates stock-summary
Company Details
2560 General Armistead Ave , AUDUBON PA : 19403-5214
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 132 Schemes (37.59%)

Foreign Institutions

Held by 209 Foreign Institutions (16.83%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Paul
Executive Chairman of the Board
Mr. David Demski
President, Chief Executive Officer, Director
Mr. David Davidar
Independent Director
Mr. Robert Douglas
Independent Director
Mr. Daniel Lemaitre
Independent Director
Ms. Ann Rhoads
Independent Director
Mr. James Tobin
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
745 Million
(Quarterly Results - Jun 2025)
Net Profit:
203 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8,042 Million (Small Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.05

stock-summary
Return on Equity

10.19%

stock-summary
Price to Book

1.87